Additionally, In the cancer patients treated with anti-PDCD1 (Pembrolizumab), anti-CD274 (Atezolizumab), or anti-CTLA4 (Ipilimumab) of the K-M plotter database, elevated KLRB1 expression exhibited better OS and progression-free survival (PFS) after grouping with KLRB1 expression median value (Figure 7 and Supplementary Figure 2A–2F). Here, CTLA4 is linked to cancer.